Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
Yurko-Mauro K, et al
Published in Alzheimers & Dementia
Methodology
Randomised, double-blind, placebo-controlled trial of 900 mg/day algal DHA for 24 weeks in adults 55+ with subjective memory complaints, with computerised CANTAB cognitive testing and plasma fatty acid measurement.
Key Findings
In the MIDAS trial, 485 healthy older adults with age-related cognitive decline took 900 mg/day algal DHA or placebo for 24 weeks; DHA nearly halved the number of errors on a paired associate learning test and improved immediate and delayed verbal recognition memory, with plasma DHA roughly doubling.
Conclusions
DHA supplementation produced measurable improvements in episodic and working memory in healthy older adults with mild age-related memory decline, supporting a benefit in pre-dementia decline rather than established Alzheimer disease.
Limitations
24-week duration cannot show whether benefits persist or prevent dementia, participants were well-educated volunteers with low baseline DHA intake, multiple cognitive endpoints raise multiplicity concerns, and the study was funded by the DHA manufacturer.
Supplements Studied
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Industry-funded (Martek Biosciences)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.